RxDoctor Payments Data

Hari Naga Garapati, MD

Nephrology · Greenville, SCNPI 1285895540

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,060 of the $4,729 with a category attached, or 64.7%. 16 manufacturers reported payments, led by Amgen at 53.0% of the total. Reporting peaked in 2024 at $2,365 and has fallen 73.4% since, to $628 in 2025.

$4,729in general payments, 2019–2025

Across 118 payments — averaging $40.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Akebia Therapeutics Inc$512
  • OPKO Pharmaceuticals, LLC$441
  • Bayer$252
  • Novartis$211
  • Vifor Pharma, Inc.$178
  • plus $627 from 10 others

What the payments were for

  • Consulting fees$1,40030%
  • Travel & lodging$100%
  • Food & beverage$3,06065%
  • Education$2595%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,729 in reported general payments places this provider in the 75th percentile of 180 nephrology providers in South Carolina.

See all nephrology providers in South Carolina

Medicare billing

Part B allowed, 2024
$160,151
Medicare patients
363
Services billed
1,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuryxiaFerric Citrate30$62,687
VelphoroSucroferric Oxyhydroxide22$40,930
KerendiaFinerenone46$40,384
FarxigaDapagliflozin Propanediol47$30,522
LokelmaSodium Zirconium Cyclosilicate22$24,411
ProsolParenteral Amino Acid 20% No.196$12,896
Sevelamer Carbonate54$8,455
Famotidine140$2,689
Calcium Acetate19$2,140
Hydralazine Hcl108$1,759
Potassium Citrate ErPotassium Citrate12$1,358
Calcitriol46$1,321
Nifedipine ErNifedipine63$1,305
Labetalol Hcl19$795
Losartan Potassium64$631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Akebia Therapeutics IncAuryxia$512$62,68730 claims
AstraZenecaFarxiga, Lokelma$93$54,93369 claims
Fresenius USA Marketing, Inc.Velphoro$134$40,93022 claims
BayerKerendia$252$40,38446 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 180 nephrology providers in South Carolina.

Other nephrology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →